|
| |
CytogenCytogen is a specialty pharmaceutical company dedicated to advancing the treatment and care of cancer patients by building, developing, and commercializing a portfolio of oncology products. The Company's specialized sales force currently markets QUADRAMET® (samarium Sm-153 lexidronam injection), PROSTASCINT® (capromab pendetide), and SOLTAMOX™ (tamoxifen citrate) to the U.S. oncology market. QUADRAMET is approved for the treatment of pain in patients whose cancer has spread to the bone, PROSTASCINT is a PSMA-targeting monoclonal antibody-based agent to image the extent and spread of prostate cancer, and SOLTAMOX is the first liquid hormonal therapy approved in the U.S. for the treatment of breast cancer in adjuvant and metastatic settings. In early 2007, Cytogen introduced its fourth approved oncology product to the U.S. market, CAPHOSOL®, an advanced electrolyte solution for the treatment of oral mucositis and dry mouth that is approved in the U.S. as a prescription medical device. The Company is also developing CYT-500, a third-generation radiolabeled antibody to treat prostate cancer. Cytogen's product-focused strategy focuses on attaining sustainable growth through clinical, commercial, and strategic initiatives.
| Contact Details: |
| 650 College Road East |
| Princeton |
| NJ |
| 08540 |
| United States of America |
| Tel: | (800) 833-3533 or (609) 750-8200 |
| Fax: | (609) 452-2476 |
| Email: | |
| WWW: | www.cytogen.com/
|
|
Loading...
|
Recent Publications by Cytogen: |  |
Cytogenetic study of professional rescue rangers of Russian Ministry of Emergencies.
Cytogenetic studies in rescue rangers of the Russian Ministry of... | 3rd October, 2008
| A. M. Nikiforov National Center of Urgent and Radiation Medicine, Ministry
| Bull Exp Biol Med. 2007 Oct;144(4):555-8.
|
Tumoral calcinosis due to GALNT3 C.516-2A >T mutation in a black African family.
Familial Tumoral Calcinosis (FTC) is a rare autosomal recessive disorder... | 10th September, 2008
| Unite de Biologie Humaine, Faculte des Sciences de la Sante, Cotonou,
| Genet Couns. 2008;19(2):183-92.
|
Indium-111 capromab pendetide in the management of recurrent prostate cancer.
The provision of accurate prognostic information is a long-standing goal... | 28th March, 2008
| The George Washington University, Washington, DC, 650 College Road East,
| Expert Rev Anticancer Ther. 2008 Feb;8(2):175-81.
DOI Direct Link |
The emergence of imaging technology in advanced prostate cancer.
Rapid advances in imaging technology have whetted our collective appetites... | 7th March, 2008
| Department of Medical Affairs, Cytogen Corporation, Princeton, NJ, USA.
| Can J Urol. 2007 Dec;14 Suppl 1:32-8.
|
Wolf Hirshhorn syndrome in a case of ring chromosome 4: phenotype and molecular cytogenetic findings.
Ring chromosome 4 associates concomitant loss of the telomeric 4p and 4q... | 17th October, 2006
| Unite de Biologie Humaine, Faculte des Sciences de la Sante, Cotonou,
| Genet Couns. 2006;17(1):35-40.
|
→View more Cytogen research publications. |
Press Releases on Cytogen:
|
 |
| Cepheid Announces European Release of Improved Test for BCR-ABL Chromosomal Translocation Associated With Chronic Myelogenous Leukemia (CML) |
17th June, 2009 |
Cepheid |
Oncology Test Further Highlights Broad Market Applicability of GeneXpert System
SUNNYVALE, Calif., June 17 /PRNewswire-FirstCall/ -- Cepheid
|
| Strategic Diagnostics Appoints Kevin J. Bratton as Chief Financial Officer |
26th May, 2009 |
Strategic Diagnostics Inc. |
NEWARK, Del., May 26 /PRNewswire-FirstCall/ -- Strategic Diagnostics Inc. (Nasdaq: SDIX) - today announced that Kevin J. Bratton has joined the Company as its Vice President of Finance and
|
| Transgenomic, Inc. Announces Appointment of New Board Members |
22nd May, 2009 |
Transgenomic, Inc. |
OMAHA, Neb., May 22 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) announces that it has appointed Antonius P. Schuh, Ph.D. and Michael B. McNulty to its Board of Directors
|
| Transgenomic and Power3 Medical Introduce NuroPro(R) Tests for Alzheimer's and Parkinson's Diseases at AAN Annual Meeting |
11th May, 2009 |
Transgenomic, Inc. |
Collaboration with Noted Neurologists to Plan Next Clinical Studies
OMAHA, Neb. and HOUSTON, May 11 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO)
|
| Transgenomic Completes Licensing Option With Dana-Farber Cancer Institute on Cold-PCR for Enrichment of DNA Mutations |
7th April, 2009 |
Transgenomic, Inc. |
OMAHA, Neb., April 7 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO), a leading global biotechnology company, announces that it has completed a licensing option with the
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 449 times since April 2007, the link to the organisation's website has been followed 76 times Recent Search Terms used to find this page: CAPHOSOL U.S. patent | cytogen | cytogen | @cytoge | cytogen | cytogen center | cytogen.com | cytogen | cytogen patents | Cytogen genes | . Search for more companies in Princeton Search for more companies in NJ This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Cytogen |
